Medscape InDiscussion: CAR T-Cell Therapy

Join Drs Amelia Langston and Frederick Locke as they discuss the future of CAR T-cell therapy research and treatment. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987070). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Cancer Immunotherapy With Chimeric Antigen Receptor (CAR) T Cells https://emedicine.medscape.com/article/2500108-overview Adoptive Cell Therapy https://www.cancer.gov/publications/dictionaries/cancer-terms/def/adoptive-cell-therapy Graft Versus Host Disease (GVHD) https://emedicine.medscape.com/article/429037-overview Multiple Myeloma https://emedicine.medscape.com/article/204369-overview BCMA in Multiple Myeloma-A Promising Key to Therapy https://pubmed.ncbi.nlm.nih.gov/34575199/ Advances in Allogeneic Cancer Cell Therapy and Future Perspectives on "Off-the-shelf" T Cell Therapy Using iPSC Technology and Gene Editing https://pubmed.ncbi.nlm.nih.gov/35053386/ Cytokine Release Syndrome https://emedicine.medscape.com/article/2500111-overview Assessing and Management of Neurotoxicity After CAR-T Therapy in Diffuse Large B-cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/34466048/ Preclinical and Clinical Studies of CAR-NK-cell Therapies for Malignancies https://pubmed.ncbi.nlm.nih.gov/36353643/ How I Treat Cytopenias After CAR T-cell Therapy https://pubmed.ncbi.nlm.nih.gov/36800563/ T-cell Receptor-based Therapy: An Innovative Therapeutic Approach for Solid Tumors https://pubmed.ncbi.nlm.nih.gov/34193217/ Biochemistry, HLA Antigens https://www.ncbi.nlm.nih.gov/books/NBK546662/ CAR T-cell Cancer Therapy Targeting Surface Cancer/Testis Antigens https://pubmed.ncbi.nlm.nih.gov/32983080/ Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges https://pubmed.ncbi.nlm.nih.gov/36077696/ Axicabtagene Ciloleucel CAR T-cell Therapy in Refractory Large B-cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/29226797/ Axicabtagene Ciloleucel as Second-line Therapy for Large B-cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/34891224/

Join Drs Amelia Langston and Jonathan L. Kaufman, MD, as they discuss current CAR–T cell for B-cell lymphomas as leading researchers and practitioners in the field. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987069). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Cancer Immunotherapy With Chimeric Antigen Receptor (CAR) T Cells https://emedicine.medscape.com/article/2500108-overview Multiple Myeloma https://emedicine.medscape.com/article/204369-overview CD19 https://www.ncbi.nlm.nih.gov/gene/930 BCMA in Multiple Myeloma - A Promising Key to Therapy https://pubmed.ncbi.nlm.nih.gov/34575199/ Histology, Plasma Cells https://www.ncbi.nlm.nih.gov/books/NBK556082/ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/33626253/ Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Patients With Relapsed or Refractory Multiple Myeloma (CARTITUDE-1): A Phase 1b/2 Open-Label Study https://pubmed.ncbi.nlm.nih.gov/34175021/ Progression-Free Survival: What Does It Mean for Psychological Well-Being or Quality of Life? [Internet] https://www.ncbi.nlm.nih.gov/books/NBK137763/ Ide-Cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/36762851/ Clinical Management of Triple-Class Refractory Multiple Myeloma: A Review of Current Strategies and Emerging Therapies https://pubmed.ncbi.nlm.nih.gov/35877215/ Bispecific Targeting of CD20 and CD19 Increases Polyfunctionality of Chimeric Antigen Receptor T-Cell Products in B-Cell Malignancies https://pubmed.ncbi.nlm.nih.gov/35597752/ Bridging Chemotherapy: Multiple Myeloma https://www.ncbi.nlm.nih.gov/books/NBK584176/ Autologous Bone Marrow Transplant https://www.cancer.gov/publications/dictionaries/cancer-terms/def/autologous-bone-marrow-transplant Myelodysplastic Syndrome (MDS) https://emedicine.medscape.com/article/207347-overview GPRC5D-Targeted CAR T Cells for Myeloma https://pubmed.ncbi.nlm.nih.gov/36170501/ Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/36507686/ Elotuzumab: The First Approved Monoclonal Antibody for Multiple Myeloma Treatment https://pubmed.ncbi.nlm.nih.gov/27493709/ Natural Killer Cells in the Malignant Niche of Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/35087536/

Join Drs Amelia Langston and Loretta Nastoupil as they discuss current CAR T-cell therapy for B-cell lymphomas as leading researchers and practitioners in the field. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987068). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Axicabtagene Ciloleucel CAR T-cell Therapy in Refractory Large B-cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/29226797/ Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/30501490/ Lisocabtagene Maraleucel for Patients With Relapsed or Refractory Large B-cell Lymphomas (TRANSCEND NHL 001): A Multicentre Seamless Design Study https://pubmed.ncbi.nlm.nih.gov/32888407/ Axicabtagene Ciloleucel as Second-line Therapy for Large B-cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/34891224/ Lisocabtagene Maraleucel Versus Standard of Care With Salvage Chemotherapy Followed by Autologous Stem Cell Transplantation as Second-line Treatment in Patients With Relapsed or Refractory Large B-cell Lymphoma (TRANSFORM): Results From an Interim Analysis of an Open-label, Randomised, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/35717989/ Second-line Tisagenlecleucel or Standard Care in Aggressive B-cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/34904798/ KTE-X19 CAR T-cell Therapy in Relapsed or Refractory Mantle-cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/32242358/ Axicabtagene Ciloleucel in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5): A Single-arm, Multicentre, Phase 2 Trial https://pubmed.ncbi.nlm.nih.gov/34895487/ Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma (ZUMA-23) https://clinicaltrials.gov/ct2/show/NCT05605899 Axicabtagene Ciloleucel in the Management of Follicular Lymphoma: Current Perspectives on Clinical Utility, Patient Selection and Reported Outcomes https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122857/

Join Drs Amelia Langston and Bijal Shah as they discuss CAR T-cell therapy for B-cell acute lymphoblastic leukemia, including clinical trials and real-world experience from their centers. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987067). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Cancer Immunotherapy With Chimeric Antigen Receptor (CAR) T Cells https://emedicine.medscape.com/article/2500108-overview Acute Lymphoblastic Leukemia (ALL) Treatment & Management https://emedicine.medscape.com/article/207631-treatment#d15 Non-Hodgkin Lymphoma (NHL) https://emedicine.medscape.com/article/203399-overview CD19 https://www.ncbi.nlm.nih.gov/gene/930 Tisagenlecleucel https://www.cancer.gov/publications/dictionaries/cancer-terms/def/tisagenlecleucel Tisagenlecleucel in Children and Young Adults With B-Cell Lymphoblastic Leukemia https://pubmed.ncbi.nlm.nih.gov/29385370/ Clinical Significance and Management of MRD in Adults With Acute Lymphoblastic Leukemia https://pubmed.ncbi.nlm.nih.gov/32903253/ Blinatumomab (Rx) https://reference.medscape.com/drug/blincyto-blinatumomab-999984#10 FDA Approves Inotuzumab for Adults With B-Cell Acute Lymphoblastic Leukemia https://www.cancer.gov/news-events/cancer-currents-blog/2017/fda-inotuzumab-leukemia Immune Effector Cell Associated Neurotoxicity Syndrome in Chimeric Antigen Receptor-T Cell Therapy https://pubmed.ncbi.nlm.nih.gov/36081506/ Cytokine Release Syndrome https://emedicine.medscape.com/article/2500111-overview Systemic Inflammatory Response Syndrome https://www.ncbi.nlm.nih.gov/books/NBK547669/ CD28 https://www.ncbi.nlm.nih.gov/gene/940 Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL) (ROCKET) https://clinicaltrials.gov/ct2/show/NCT02535364 KTE-X19 for Relapsed or Refractory Adult B-Cell Acute Lymphoblastic Leukaemia: Phase 2 Results of the Single-Arm, Open-label, Multicentre ZUMA-3 Study https://pubmed.ncbi.nlm.nih.gov/34097852/ CAR T-Cell Therapy Approved for Some Children and Young Adults With Leukemia https://www.cancer.gov/news-events/cancer-currents-blog/2017/tisagenlecleucel-fda-childhood-leukemia Allogeneic Stem Cell Transplant https://www.cancer.gov/publications/dictionaries/cancer-terms/def/allogeneic-stem-cell-transplant clonoSEQ Assay https://ous.clonoseq.com/for-clinicians/how-clonoseq-works/ Management of Hypogammaglobulinaemia and B-Cell Aplasia https://www.ncbi.nlm.nih.gov/books/NBK584138/ Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse After Tisagenlecleucel in Children and Young Adults With Acute Lymphoblastic Leukemia https://pubmed.ncbi.nlm.nih.gov/35019853/ Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial https://pubmed.ncbi.nlm.nih.gov/36399695/ Therapeutic Targeting of Mutated p53 in Acute Lymphoblastic Leukemia https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6939537/ MLL-Rearranged Acute Lymphoblastic Leukemia https://pubmed.ncbi.nlm.nih.gov/32350732/ Liposomal Vincristine for Relapsed or Refractory Ph-Negative Acute Lymphoblastic Leukemia: A Review of Literature https://pubmed.ncbi.nlm.nih.gov/24490021/ Consolidation Therapy With Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients With B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results From the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial https://ashpublications.org/blood/article/140/Supplement%202/LBA-1/493429/Consolidation-Therapy-with-Blinatumomab-Improves

Join Drs Amelia Langston and Jean Koff as they discuss the monitoring and management of complications before, during, and after CAR T therapy. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987066). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Cancer Immunotherapy With Chimeric Antigen Receptor (CAR) T Cells https://emedicine.medscape.com/article/2500108-overview Cytokine Release Syndrome https://emedicine.medscape.com/article/2500111-overview Immune Effector Cell Associated Neurotoxicity Syndrome in Chimeric Antigen Receptor-T Cell Therapy https://pubmed.ncbi.nlm.nih.gov/36081506/ On-target and Off-target-based Toxicologic Effects https://pubmed.ncbi.nlm.nih.gov/23085982/ Cytokine https://www.cancer.gov/publications/dictionaries/cancer-terms/def/cytokine Tocilizumab (Rx) https://reference.medscape.com/drug/actemra-tocilizumab-999419 CARTOX 10 Point Neurological Assessment https://reference.medscape.com/viewarticle/886616_5 Levetiracetam https://www.ncbi.nlm.nih.gov/books/NBK499890/ Cytopenia After CAR-T Cell Therapy-A Brief Review of a Complex Problem https://pubmed.ncbi.nlm.nih.gov/35326654/ Immune Effector Cell-associated Hemophagocytic Lymphohistiocytosis-like Syndrome https://pubmed.ncbi.nlm.nih.gov/36906275/ Management of Hypogammaglobulinaemia and B-cell Aplasia https://www.ncbi.nlm.nih.gov/books/NBK584138/ Rituximab (Rx) https://reference.medscape.com/drug/rituxan-truxima-rituximab-342243 Bispecific Targeting of CD20 and CD19 Increases Polyfunctionality of Chimeric Antigen Receptor T-cell Products in B-cell Malignancies https://pubmed.ncbi.nlm.nih.gov/35597752/ Mantle Cell Lymphoma https://www.ncbi.nlm.nih.gov/books/NBK536985/ Chimeric Antigen Receptor (CAR) T-cell Treatment for Mantle Cell Lymphoma (MCL) https://pubmed.ncbi.nlm.nih.gov/35237395/ Apheresis https://www.cancer.gov/publications/dictionaries/cancer-terms/def/apheresis